Efficacy of Clobazam as Add-on AED in Partial Onset Seizures Management (P4.267)

Objective: To study the effectiveness of CLB as an Add-on AED in treatment of medically refractory POS. Background: In spite of several new antiepileptic drugs (AED), over 30% of the patients with partial onset seizures (POS) remain medically refractory. Clobazam (CLB) is approved by FDA for treatment of seizures in patients with Lennox Gestaut syndrome (LGS). It is approved and being used in other countries for other type of seizures including POS. However, the efficacy of CLB as an Add-on AED in treatment of POS was never studied in the US. Design/Methods: In our retrospective chart review, all patients who were started on CLB during years 2006 – 2015 were included in the study. The patients with diagnosis of LGS or primary generalized epilepsy and/or lack follow-up information was excluded. In all qualifying patients the Age, Sex, Race, seizure duration, etiology, seizure frequency, dose of AEDs, introduction of a new AED, side effects of AED at each time point of 3 months, 6 months and 1 year were noted. The efficacy was tabulated as reduction in seizure frequency from the baseline; 90% reduction or seizure free. Results: Of the 47 patients, the 50% responder rate was 50%, 60% and 45% at 3 month, 6 month and 1 yr. Greater than 90% seizure reduction was in 15%, 10%, 20% at 3 month, 6 month and 1 yr. Seizure freedom was achieved in 10%, 15%, 10% at 3 month, 6 month and 1 yr. Conclusions: Clobazam as an Add-on AED is effective in patients with medically refractory partial onset seizures. Further analyses comparing the efficacy of other AEDs may predict the Add-on medication with better efficacy and potential effective medication regimens in controlling POS. Disclosure: Dr. Shah has nothing to disclose. Dr. Yarraguntla has nothing to disclose. Dr. Zutshi has nothing to disclose. Dr. Basha has nothing to disclose. Dr. Bathe has nothing to disclose.